In DepthInfectious Diseases

Controversy over dengue vaccine risk

See allHide authors and affiliations

Science  06 Sep 2019:
Vol. 365, Issue 6457, pp. 961-962
DOI: 10.1126/science.365.6457.961

You are currently viewing the summary.

View Full Text

Log in to view the full text

Log in through your institution

Log in through your institution

Summary

Shortly after Dengvaxia came to market in 2015, the Philippines launched a massive campaign to immunize children against the dreaded diseases. After about 1 million children were vaccinated, Sanofi Pasteur, the Paris-based maker of the product, revealed that ongoing clinical trials had found a rare, dangerous complication. Four distinct variants of dengue infect humans. In a well-known phenomenon, people infected with one strain who become infected with a second one become vulnerable to severe dengue, which can cause life-threatening shock and hemorrhagic fever. The vaccine, when given to children who had never been infected with dengue, primes some for that rare phenomenon of severe disease. Now, some researchers are calling for studies that would test the vaccinated children and identify the ones most at risk. They contend that if parents knew their children were at increased risk of severe disease, they could more aggressively seek care if they suspected dengue. This also might alleviate confusion for some parents who have blamed the vaccine for the death of their children. But no one has sponsored the study yet.

View Full Text